Media
29 July 2024
4basebio PLC Announces £40.0 million Equity Issuance and £29.4 million Secondary Sale
10 APRIL 2024
4basebio announces the supply of its opDNA™ DNA products into Tier 1 Pharma client’s vaccine program
21 MARCH 2024
4basebio announces key milestone with its client progressing into Phase I clinical trials of an mRNA vaccine manufactured from 4basebio’s opDNA™
01 MARCH 2024
4basebio awarded tender to deliver research and GMP-grade synthetic DNA in CPI’s tender process for supplying its RNA Centre of Excellence
01 AUGUST 2023
4basebio receives grant to advance its synthetic DNA platform and HermesTM nanoparticle platform for the development of thermostable nucleic acid vaccines
25 MAY 2023
4basebio and Neomatrix announce clinical material supply agreement to develop personalised cancer therapy utilising 4basebio’s proprietary hpDNATM.
27 APRIL 2022
Joint Development Agreement with Heqet Therapeutics
for development of a non-viral vector therapy for cardiac regeneration
23 MARCH 2022
Rapidly produced customisable synthetic DNA
18 JANUARY 2022
Strategic Research Collaboration
evaluating linear DNA for mRNA production
23 november 2021
Joint Development Agreement with Leucid Bio for novel CAR T-cell production methods
22 june 2021
Patent Application
27 april 2021
